Histogenics Corporation is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company�s first product candidate, NeoCart, is being investigated in a Phase III clinical trial. NeoCart utilizes regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. Its regenerative medicine platform consists of bioengineering, materials sciences, molecular and cellular biology technologies that can be utilized individually or in a variety of combinations to treat musculoskeletal-related conditions, including cell processing, Scaffolds, tissue engineering, bioadhesives and growth factors. NeoCart is a cartilage-like implant created using a patient�s own cartilage cells through a series of tissue engineering processes.